Isofol Medical: Post-ASCO update
Research Note
2019-06-05
22:27
The annual meeting of the annual meeting of the American Society of Clinical Oncology (ASCO) is now over. No major, practise-changing advances were seen in colorectal cancer (CRC), but we saw some interesting results in the early stage pipeline and will monitor the development going forward. Overall, we continue to view Isofol’s competitive landscape as favourable.
AN
Arvid Necander
Disclosures and disclaimers